Polaris Industries Inc. (PII)
Brokerage firm RBC Capital Markets upgraded PII shares from Sector Perform to Outperform and raised its price target from $155.00 to $158.00
PIIrecently reported second quarter 2015 sales of $1.12 billion and net income of $100.9 million, or $1.49 per diluted share for the period
PIIis a recognized leader in the powersports industry with annual 2014 sales of $4.5 billion.
Xylem Inc. (XYL)
Investment analysts at Stifel Nicolaus upgraded the shares of XYL from Hold to Buy with a price target of $37.00
XYL delivered second quarter 2015 revenue of $920 million and adjusted net income (excluding non-recurring items) of $78 million or $0.43 per share for the period
XYL is a leading global water technology provider, enabling customers to transport, treat, test and efficiently use water in public utility, residential and commercial building services, industrial and agricultural settings.
Kite Pharma, Inc. (KITE)
FBR Capital initiated coverage on KITE shares with a Market Perform rating and a price target of $64.00
KITEwill participate in the 10th Annual Citi Biotech Conference on Thursday, September 10, 2015 and the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015
KITE is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous T-cell eACT(TM) designed to restore the immune system’s ability to recognize and eradicate tumors.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer